StockData
Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc. (CADL) stock

CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 1/30
$5.32−0.08 (-1.48%)

Close on Nov 18, 2026Market cap $407.08MP/E –Yield –

Candel Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Candel Therapeutics's revenue for the twelve months ending Dec 31, 2022 was $125.00K, up 0.0% year over year. For fiscal 2022 it was $125.00K, up 0.0% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2022Dec 31, 2022$125.00K0.0%
FY2021Dec 31, 2021$125.00K0.0%
FY2020Dec 31, 2020$125.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2022Dec 31, 2022$31.00K0.0%
Q3 FY2022Sep 30, 2022$31.00K0.0%
Q2 FY2022Jun 30, 2022$31.00K0.0%
Q1 FY2022Mar 31, 2022$31.00K0.0%
Q4 FY2021Dec 31, 2021$31.00K0.0%
Q3 FY2021Sep 30, 2021$31.00K0.0%
Q2 FY2021Jun 30, 2021$31.00K0.0%
Q1 FY2021Mar 31, 2021$31.00K–
Q4 FY2020Dec 31, 2020$31.00K–
Q3 FY2020Sep 30, 2020$31.00K–
Q2 FY2020Jun 30, 2020$31.00K–

More Candel Therapeutics figures

See a number that looks wrong?